Biotechnology agency Biogen Inc. (NASDAQ: BIIB) Thursday reported a year-over-year lower in adjusted revenue for the primary quarter of 2025, regardless of a rise in revenues.
Complete income rose 6% year-over-year to $2.4 billion within the March quarter. For the total yr of 2025, the corporate expects revenues to say no by a mid-single-digit proportion yearly, at fixed foreign money, and tasks adjusted earnings per share within the vary of $14.50 to $15.50.
Web earnings attributable to Biogen was $240.5 million or $1.64 per share in Q1, down 39% from the prior-year interval. Adjusted earnings decreased 18% yearly to $3.02 per share within the first quarter.
